1114872--3/19/2008--MILLENNIUM_CELL_INC

related topics
{stock, price, share}
{product, candidate, development}
{product, market, service}
{acquisition, growth, future}
{stock, price, operating}
{debt, indebtedness, cash}
{system, service, information}
{financial, litigation, operation}
{personnel, key, retain}
{property, intellectual, protect}
{gas, price, oil}
{interest, director, officer}
{product, liability, claim}
{competitive, industry, competition}
There is substantial doubt about our ability to continue as a going concern and we have an immediate need for working capital. We need future capital to complete our product development and commercialization plans. If we are able to raise additional capital, it may dilute our existing stockholders or restrict our ability to operate our business. We expect our future operating results to vary from quarter to quarter, and increase the likelihood that we may fail to meet the expectations of securities analysts and investors at any given time. We may be subject to litigation resulting from common stock volatility, which may result in substantial costs and a diversion of our management s attention and resources and could have a negative effect on our business and results of operations. If we or our collaborative partners fail to perform under our joint development and research agreements, our ability to commercialize our proposed products could be impaired. We rely on government funding for certain research and development and technology demonstration projects. Our future plans could be adversely affected if we are unable to attract or retain key personnel. If we are unable to continue to complete prototype development and engineering of commercially viable hydrogen batteries, we will not be able to build our business as anticipated. Failure to meet milestones and performance goals with potential customers could delay or impede commercialization of our technology. Potential purchasers of our systems may decline to purchase our technology or choose to purchase alternate technologies. Our hydrogen fuel cartridge technology may only be commercially viable as a component of other companies products, and these companies may choose not to include our systems in their products. Any perceived problem while conducting demonstrations of our technology could hurt our reputation and the reputation of our products, which could impede the development of our business. Our failure to obtain, maintain or protect the right to use certain intellectual property may negatively affect our business. Any accidents involving our products or the raw materials used in our products could impair their market acceptance. Our outstanding unsecured convertible debentures are subject to mandatory prepayments at the option of the holders thereof upon certain conditions which, if exercised, will have a material adverse effect on our financial condition and our business. We may be required to issue more shares of common stock upon adjustment of the conversion price of our outstanding preferred stock and unsecured convertible debentures or the exercise price of our outstanding warrants, resulting in dilution of our existing stockholders. Sales of substantial amounts of common stock in the public market could reduce the market price of our common stock and make it more difficult for us and our stockholders to sell our equity securities in the future. We do not intend to pay any dividends on our common stock. If we fail to meet all applicable NASDAQ Capital Market listing requirements and such exchange determines to delist our common stock, the delisting could adversely affect the market liquidity of our common stock and the market price of our common stock could decline. A mass market for our products may never develop or may take longer to develop than we anticipate. We will continue to face intense competition from energy technology companies and may be unable to compete successfully.

Full 10-K form ▸

related documents
876043--1/16/2007--MEDWAVE_INC
1017491--3/16/2006--NEXMED_INC
1114872--3/30/2007--MILLENNIUM_CELL_INC
849636--3/15/2007--CORTEX_PHARMACEUTICALS_INC/DE/
12239--3/31/2006--SPHERIX_INC
3116--3/30/2006--AKORN_INC
12239--4/2/2007--SPHERIX_INC
1060888--9/14/2009--LIFEQUEST_WORLD_CORP
1450552--12/29/2010--Dafoe_Corp.
3116--3/16/2007--AKORN_INC
749647--3/20/2006--CELSION_CORP
1017491--3/26/2007--NEXMED_INC
1298700--11/17/2008--Verdant_Technology_CORP
849636--4/15/2009--CORTEX_PHARMACEUTICALS_INC/DE/
849636--3/17/2008--CORTEX_PHARMACEUTICALS_INC/DE/
3116--3/16/2010--AKORN_INC
1371128--3/25/2008--BioSolar_Inc
838879--4/15/2010--RADIENT_PHARMACEUTICALS_Corp
874443--3/22/2007--GENELABS_TECHNOLOGIES_INC_/CA
71478--3/28/2008--LIPID_SCIENCES_INC/
838879--3/31/2008--AMDL_INC
1091356--3/31/2008--SEAENA_INC.
1079028--11/26/2008--VARIAN_INC
1298700--4/15/2009--Verdant_Technology_CORP
1017491--3/12/2008--NEXMED_INC
867840--9/26/2008--PRECISION_OPTICS_CORPORATION_INC
1059784--10/16/2006--GENEREX_BIOTECHNOLOGY_CORP
797167--4/13/2006--NATURADE_INC
1011733--4/15/2009--TRIMOL_GROUP_INC
1063197--4/11/2008--TORVEC_INC